title: Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.
abstract: The recent approval of buprenorphine for the treatment of opiate dependence offers an opportunity to analyze innovation adoption in community-based treatment. Using data collected from national samples of 299 privately funded and 277 publicly funded treatment centers, this research examines buprenorphine adoption using baseline data collected between 2002 and 2004 as well as follow-up data collected 12 months later. Private centers were significantly more likely than public centers to report current use of buprenorphine. The baseline data indicated that early adoption was positively associated with center accreditation, physician services, availability of detoxification services, current use of naltrexone, and the percentage of opiate-dependent clients. Multivariate analyses of follow-up data suggest that adoption was greater in accredited centers, for-profit facilities, organizations offering detoxification services, and naltrexone-using centers. Future research should continue to monitor the extent to which buprenorphine is adopted in these settings.
authors.affiliation: Center for Research on Behavioral Health and Human Services Delivery, The University of Georgia, 101 Barrow Hall, Athens, GA 30602-2401, USA. hknudsen@uga.edu
authors.forename: Hannah K
authors.initials: HK
authors.lastname: Knudsen
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Ducharme
authors.forename: Paul M
authors.initials: PM
authors.lastname: Roman
mesh_terms: D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D004363:Drug Utilization; D006801:Humans; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D017149:Private Sector; D017150:Public Sector; D016320:Substance Abuse Treatment Centers / Q000600:supply & distribution; D019966:Substance-Related Disorders / Q000188:drug therapy*; D014481:United States
chemical_list: D009292:Narcotic Antagonists; D002047:Buprenorphine